Company Profile

LUPIN LTD.

NSE : LUPINBSE : 500257ISIN CODE : INE326A01037Industry : Pharmaceuticals & DrugsHouse : Lupin
BSE1081.852.3 (+0.21 % )
PREV CLOSE (Rs.) 1079.55
OPEN PRICE (Rs.) 1085.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 249783
TODAY'S LOW / HIGH (Rs.)1049.95 1103.65
52 WK LOW / HIGH (Rs.)505 1121.85
NSE1081.90 2.65 (+0.25 % )
PREV CLOSE(Rs.) 1079.25
OPEN PRICE (Rs.) 1092.00
BID PRICE (QTY) 1081.90 (3805 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3538003
TODAY'S LOW / HIGH(Rs.) 1049.25 1103.70
52 WK LOW / HIGH (Rs.)504.75 1122.3

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.03
Dividend Yield(%) 0.55
TTM EPS (Rs.) 19.13
P/E Ratio 56.55
Book Value (Rs.) 396.67
Face Value (Rs.) 2
MCap (Rs. in Mn) 490724.17
Price/Earning (TTM) 35.67
Price/Sales (TTM) 4.57
Price/Book (MRQ) 2.73
PAT Margin (%) 6.13
ROCE (%) 6.39
Incorporation Year : 1983

Management Info :

Manju D Gupta - Chairman Nilesh Gupta - Managing Director

Registered Office :

Address : Kalpataru Inspire, 3rd Floor,Off. Western Express Highway,Santacruz (East),
Mumbai,
Maharashtra-400055

Phone : 022 6640 2323

Website : www.lupinworld.com

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
25Jan01-25-2021$Lupin gets approval for Sevelamer Carbonate Tablets Lupin gets approval for Seve

Lupin has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.

Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin has received approval for its Sevelamer Carbonate Tablets..
25Jan01-25-2021$Lupin informs about press release Lupin informs about press re

Lupin has informed that it has enclosed a Press Release as regards receipt of USFDA approval for the Company's Sevelamer Carbonate Tablets, 800 mg, to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.

The above information is a part of company’s filings submitted to BSE.

Lupin has informed that it has enclosed a Press Release as rega..
25Jan01-25-2021$Lupin rises on getting approval for Sevelamer Carbonate Tablets Lupin rises on getting appro

Lupin is currently trading at Rs. 1085.95, up by 6.40 points or 0.59% from its previous closing of Rs. 1079.55 on the BSE.

The scrip opened at Rs. 1085.00 and has touched a high and low of Rs. 1103.65 and Rs. 1049.95 respectively. So far 233596 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1121.85 on 18-Sep-2020 and a 52 week low of Rs. 505.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 1103.65 and Rs. 1034.55 respectively. The current market cap of the company is Rs. 49333.24 crore.

The promoters holding in the company stood at 46.88%, while Institutions and Non-Institutions held 40.05% and 12.79% respectively.

Lupin has received approval for its Sevelamer Carbonate Tablets, 800 mg, from the United States Food and Drug Administration, to market a generic equivalent of Renvela Tablets, 800 mg, of Genzyme Corporation.

Sevelamer Carbonate Tablets, 800 mg, are indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

 

Lupin is currently trading at Rs. 1085.95, up by 6.40 points or..
18Jan01-18-2021$Lupin informs about earnings call Lupin informs about earnings
Lupin has informed that Earnings Call for Quarter - Ill, FY 2021 is scheduled on Friday, January 29, 2021 at 08.00 hrs (IST).

The above information is a part of company’s filings submitted to BSE.
.
Lupin has informed that Earnings Call for Quarter - Ill, FY 202..
11Jan01-11-2021$Lupin informs about analyst meet Lupin informs about analyst
Lupin has informed that the company will be participating in the J P Morgan Global Healthcare Conference to be held on Tuesday, January 12, 2021.

The above information is a part of company’s filings submitted to BSE.

Lupin has informed that the company will be participating in th..
Financials More
Rs. in Millions
QTR Sep 20 ANNUAL 20
Net Profit3604.37275.5
Gross Profit 4883.4 10522.5
Operating Profit 6230.723828
Net Sales 30426110256.6
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 14535.90 (0.84%)
M.Cap ( in Cr)
30887.77
Alkem Laboratories (BSE)
 3110.05 (2.51%)
M.Cap ( in Cr)
37185.31
Aurobindo Pharma (BSE)
 998.00 (8.05%)
M.Cap ( in Cr)
58476.67
JB Chem & Pharma (BSE)
 1046.45 (5.34%)
M.Cap ( in Cr)
8087.19
Dr. Reddys Lab (BSE)
 5082.10 (0.96%)
M.Cap ( in Cr)
84514.37
Shareholding Pattern More
FI/BANKS/INSURANCE 7.75 %
PROMOTERS 46.88 %
FII 18.97 %
MUTUAL FUNDS/UTI 13.21 %
NON-INSTITUTION 12.79 %
GOVERNMENT 0.29 %
F & O Quotes